Psoriasis drug discovery: methods for evaluation of potential drug candidates

Bibliography

• Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis-Part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 2011;127:1420-32
   PubMed Web of Science ®Google Scholar
• Elder JT, Bruce AT, Gudjonsson JE, Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 2010;130:1213-26
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339-50
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128:1207-11
   PubMed Web of Science ®Google Scholar
• Nair RP, Stuart PE, Nistor I, Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006;78:827-51
   PubMed Web of Science ®Google Scholar
• Nair RP, Ruether A, Stuart PE, Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008;128:1653-61
   PubMed Web of Science ®Google Scholar
• Nair RP, Duffin KC, Helms C, Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199-204
   PubMed Web of Science ®Google Scholar
• Feng BJ, Sun LD, Soltani-Arabshahi R, Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet 2009;5:e1000606
   PubMed Web of Science ®Google Scholar
• de Cid R, Riveira-Munoz E, Zeeuwen PL, Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009;41:211-15
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Huang W, Yang S, Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet 2009;41:205-10
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Di Cesare A, Laggner U, The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One 2011;6:e17160
   PubMed Web of Science ®Google Scholar
• Mossner R, Reich K. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab. Curr Probl Dermatol 2009;38:107-36
   PubMedGoogle Scholar
• Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011;71:1733-53
   PubMed Web of Science ®Google Scholar
• Paul C, Gallini A, Maza A, Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):2-11
   PubMed Web of Science ®Google Scholar
• van Lumig P, Driessen R, Berends M, Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol 2011; doi: 10.1111/j.1468-3083.2011.04044.x.
   PubMed Web of Science ®Google Scholar
• Augustin M, Holland B, Dartsch D, Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011;222:363-74
   PubMed Web of Science ®Google Scholar
• Available from: clinicaltrials.gov
   Google Scholar
• Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol 2011;391-414
   PubMedGoogle Scholar
• Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 2011;32:25-34
   PubMed Web of Science ®Google Scholar
• Chang T, Sun L, Wang Y, Inhibition of keratin 17 expression with antisense and RNAi strategies: exploring novel therapy for psoriasis. Exp Dermatol 2011;20:555-60
   PubMed Web of Science ®Google Scholar
• Jakobsen M, Stenderup K, Rosada C, Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model. Mol Ther 2009;17:1743-53
   PubMed Web of Science ®Google Scholar
• Swanson R, Beasley JR. Pathway-specific, species, and sub-type counterscreening for better GPCR hits in high throughput screening. Curr Pharm Biotechnol 2010;11:757-63
   PubMed Web of Science ®Google Scholar
• Pastore S, Lulli D, Potapovich AI, Differential modulation of stress-inflammation responses by plant polyphenols in cultured normal human keratinocytes and immortalized HaCaT cells. J Dermatol Sci 2011;63:104-14
   PubMed Web of Science ®Google Scholar
• Ridd K, Dhir S, Smith AG, Defective TPA signalling compromises HaCat cells as a human in vitro skin carcinogenesis model. Toxicol In Vitro 2010;24:910-15
   PubMed Web of Science ®Google Scholar
• Lewis DA, Hengeltraub SF, Gao FC, Aberrant NF-kappaB activity in HaCaT cells alters their response to UVB signaling. J Invest Dermatol 2006;126:1885-92
   PubMed Web of Science ®Google Scholar
• Ratnam AV, Bikle DD, Su MJ, Squamous carcinoma cell lines fail to respond to 1,25-Dihydroxyvitamin D despite normal levels of the vitamin D receptor. J Invest Dermatol 1996;106:522-5
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 2006;7:243
   PubMed Web of Science ®Google Scholar
• Sonkoly E, Wei T, Janson PC, MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2007;2:e610
   PubMed Web of Science ®Google Scholar
• Zibert JR, Lovendorf MB, Litman T, MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci 2010;58:177-85
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159:842-55
   PubMed Web of Science ®Google Scholar
• Burgler S, Ouaked N, Bassin C, Differentiation and functional analysis of human T(H)17 cells. J Allergy Clin Immunol 2009;123:588-95. 595
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234-43
   PubMed Web of Science ®Google Scholar
• Sano S, Chan KS, Carbajal S, Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005;11:43-9
   PubMed Web of Science ®Google Scholar
• Swindell WR, Johnston A, Carbajal S, Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One 2011;6:e18266
   PubMed Web of Science ®Google Scholar
• Nakajima K, Kanda T, Takaishi M, Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 2011;186:4481-9
   PubMed Web of Science ®Google Scholar
• van der Fits L, Mourits S, Voerman JS, Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009;182:5836-45
   PubMed Web of Science ®Google Scholar
• Patel U, Mark NM, Machler BC, Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol 2011;164:670-2
   PubMed Web of Science ®Google Scholar
• Chan JR, Blumenschein W, Murphy E, IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87
   PubMed Web of Science ®Google Scholar
• Lindroos J, Svensson L, Norsgaard H, IL-23-mediated epidermal hyperplasia is dependent on IL-6. J Invest Dermatol 2011;131:1110-18
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509
   PubMed Web of Science ®Google Scholar
• Heidenreich R, Rocken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009;90:232-48
   PubMed Web of Science ®Google Scholar
• Halin C, Fahrngruber H, Meingassner JG, Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 2008;173:265-77
   PubMed Web of Science ®Google Scholar
• Abe R, Yamagishi S, Fujita Y, Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis. J Dermatol Sci 2010;57:183-91
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in psoriasis: therapeutic implications. J Invest Dermatol 1972;59:40-3
   PubMed Web of Science ®Google Scholar
• Nacev B, Low WK, Huang Z, A calcineurin-independent mechanism of angiogenesis inhibition by a non-immunosuppressive Cyclosporin A analog. J Pharmacol Exp Ther 2011;338:466-75
   PubMed Web of Science ®Google Scholar
• Rossi B, Schinzari G, Maccauro G, Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord 2010;11:34
   PubMedGoogle Scholar
• Sethi G, Sung B, Kunnumakkara AB, Targeting TNF for treatment of cancer and autoimmunity. Adv Exp Med Biol 2009;647:37-51
   PubMed Web of Science ®Google Scholar
• Micali G, Lacarrubba F, Musumeci ML, Cutaneous vascular patterns in psoriasis. Int J Dermatol 2010;49:249-56
   PubMed Web of Science ®Google Scholar
• Garcia-Caballero M, Mari-Beffa M, Medina MA, Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect? J Invest Dermatol 2011;131:1347-55
   PubMed Web of Science ®Google Scholar
• Narayanan S, Callis-Duffin K, Batten J, Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci 2010;339:580-1
   PubMed Web of Science ®Google Scholar
• Akman A, Yilmaz E, Mutlu H, Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol 2009;34:e202-4
   PubMed Web of Science ®Google Scholar
• Sauder DN, Dekoven J, Champagne P, Neovastat (AE-941), an inhibitor of angiogenesis: randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 2002;47:535-41
   PubMed Web of Science ®Google Scholar
• Voskas D, Jones N, Van SP, A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 2005;166:843-55
   PubMed Web of Science ®Google Scholar
• Detmar M, Brown LF, Schon MP, Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998;111:1-6
   PubMed Web of Science ®Google Scholar
• Kunstfeld R, Hirakawa S, Hong YK, Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 2004;104:1048-57
   PubMed Web of Science ®Google Scholar
• Hvid H, Teige I, Kvist PH, TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Int Immunol 2008;20:1097-106
   PubMed Web of Science ®Google Scholar
• Teige I, Hvid H, Svensson L, Regulatory T cells control VEGF-dependent skin inflammation. J Invest Dermatol 2009;129:1437-45
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ibe M, Kinouchi M, Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 2003;31:21-8
   PubMed Web of Science ®Google Scholar
• Bernard FX, Pedretti N, Rosdy M, Comparison of gene expression profiles in human keratinocyte mono-layer cultures, reconstituted epidermis and normal human skin; transcriptional effects of retinoid treatments in reconstituted human epidermis. Exp Dermatol 2002;11:59-74
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011;131:677-87
   PubMed Web of Science ®Google Scholar
• Boniface K, Bernard FX, Garcia M, IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005;174:3695-702
   PubMed Web of Science ®Google Scholar
• Sa SM, Valdez PA, Wu J, The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007;178:2229-40
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Guttman-Yassky E, Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159:1092-102
   PubMed Web of Science ®Google Scholar
• Wolk K, Haugen HS, Xu W, IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009;87:523-36
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Ding J, Johnston A, Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 2010;130:1829-40
   PubMed Web of Science ®Google Scholar
• Guilloteau K, Paris I, Pedretti N, Skin inflammation induced by the synergistic action of IL-17A, IL-22, Oncostatin M, IL-1{alpha}, and TNF-{alpha} recapitulates some features of psoriasis. J Immunol 2010;184:5263-70
   PubMed Web of Science ®Google Scholar
• Tjabringa G, Bergers M, van RD, Development and validation of human psoriatic skin equivalents. Am J Pathol 2008;173:815-23
   PubMed Web of Science ®Google Scholar
• Jean J, Lapointe M, Soucy J, Development of an in vitro psoriatic skin model by tissue engineering. J Dermatol Sci 2009;53:19-25
   PubMed Web of Science ®Google Scholar
• Barker CL, McHale MT, Gillies AK, The development and characterization of an in vitro model of psoriasis. J Invest Dermatol 2004;123:892-901
   PubMed Web of Science ®Google Scholar
• Konstantinova NV, Duong DM, Remenyik E, Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. J Invest Dermatol 1996;107:615-21
   PubMed Web of Science ®Google Scholar
• Jean J, Soucy J, Pouliot R. Effects of retinoic acid on keratinocyte proliferation and differentiation in a psoriatic skin model. Tissue Eng Part A 2011;17:1859-68
   PubMed Web of Science ®Google Scholar
• Schon MP. Animal models of psoriasis: a critical appraisal. Exp Dermatol 2008;17:703-12
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Johnston A, Dyson M, Mouse models of psoriasis. J Invest Dermatol 2007;127:1292-308
   PubMed Web of Science ®Google Scholar
• Han G, Williams CA, Salter K, A role for TGFbeta signaling in the pathogenesis of psoriasis. J Invest Dermatol 2010;130:371-7
   PubMed Web of Science ®Google Scholar
• Michaelis K, Wallbrecht K, Kerstan A, Modulating T cell functions does not alleviate chronic inflammatory skin lesions in K5.TGF beta 1 transgenic mice. Exp Dermatol 2010;19:406-15
   PubMed Web of Science ®Google Scholar
• Carroll JM, Romero MR, Watt FM. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell 1995;83:957-68
   PubMed Web of Science ®Google Scholar
• Teige I, Backlund A, Svensson L, Induced keratinocyte hyper-proliferation in alpha2beta1 integrin transgenic mice results in systemic immune cell activation. Int Immunopharmacol 2010;10:107-14
   PubMed Web of Science ®Google Scholar
• Koegel H, von TL, Schafer M, Loss of serum response factor in keratinocytes results in hyperproliferative skin disease in mice. J Clin Invest 2009;119:899-910
   PubMed Web of Science ®Google Scholar
• Romanowska M, Reilly L, Palmer CN, Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo. PLoS ONE 2010;5:e9701
   PubMed Web of Science ®Google Scholar
• Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004;172:2731-8
   PubMed Web of Science ®Google Scholar
• Annunziato F, Romagnani S. Do studies in humans better depict Th17 cells? Blood 2009;114:2213-19
   PubMed Web of Science ®Google Scholar
• Kvist PH, Svensson L, Hagberg O, Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model. J Transl Med 2009;7:107
   PubMedGoogle Scholar
• Sugai J, Iizuka M, Kawakubo Y, Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice. J Dermatol Sci 1998;17:85-92
   PubMed Web of Science ®Google Scholar
• Stenderup K, Rosada C, Dam TN, Resolution of psoriasis by a leukocyte-targeting bacterial protein in a humanized mouse model. J Invest Dermatol 2011;131:2033-9
   PubMed Web of Science ®Google Scholar
• Stenderup K, Rosada C, Alifrangis L, Statistical evaluation and experimental design of a psoriasis xenograft transplantation model treated with cyclosporin A. Exp Dermatol 2011;20:441-4
   PubMed Web of Science ®Google Scholar
• Bak RO, Stenderup K, Rosada C, Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin. BMC Dermatol 2011;11:5
   PubMedGoogle Scholar
• Stenderup K, Rosada C, Worsaae A, Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2009;160:284-96
   PubMed Web of Science ®Google Scholar
• Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996;98:1878-87
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999;155:145-58
   PubMed Web of Science ®Google Scholar
• Boyman O, Hefti HP, Conrad C, Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004;199:731-6
   PubMed Web of Science ®Google Scholar
• Conrad C, Boyman O, Tonel G, Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 2007;13:836-42
   PubMed Web of Science ®Google Scholar
• Dinh PH, Corazza F, Mestdagh K, Validation of the cantharidin-induced skin blister as an in vivo model of inflammation. Br J Clin Pharmacol 2011; doi: 10.1111/j.1365-2125.2011.04020.x
   PubMed Web of Science ®Google Scholar
• Dumas KJ, Scholtz JR. The psoriasis bio-assay for topical corticosteroid activity. Acta Derm Venereol 1972;52:43-8
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Graeber M, Brautigam M, The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-6
   PubMed Web of Science ®Google Scholar
• Remitz A, Reitamo S, Erkko P, Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999;141:103-7
   PubMed Web of Science ®Google Scholar
• Rappersberger K, Meingassner JG, Fialla R, Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996;106:701-10
   PubMed Web of Science ®Google Scholar
• Bangha E, Elsner P. Evaluation of topical antipsoriatic treatment by chromametry, visiometry and 20-MHz ultrasound in the psoriasis plaque test. Skin Pharmacol 1996;9:298-306
   PubMedGoogle Scholar
• Buder K, Knuschke P, Wozel G. Evaluation of methylprednisolone aceponate, tacrolimus and combination thereof in the psoriasis plaque test using sum score, 20-MHz-ultrasonography and optical coherence tomography. Int J Clin Pharmacol Ther 2010;48:814-20
   PubMed Web of Science ®Google Scholar
• Benson NR, Papenfuss J, Wong R, An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvesting. J Invest Dermatol 2006;126:2234-41
   PubMed Web of Science ®Google Scholar
• Macdonald N, Cumberbatch M, Singh M, Proteomic analysis of suction blister fluid isolated from human skin. Clin Exp Dermatol 2006;31:445-8
   PubMed Web of Science ®Google Scholar
• Salgo R, Thaci D, Boehncke S, Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy. Exp Dermatol 2011;20:130-3
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Wustlich S, Hoexter G, An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003;83:351-3
   PubMed Web of Science ®Google Scholar
• Parmar H. The application of advanced emerging technologies to novel biomarker discovery, target validation and earlier clinical Proof of Principle in Pharma R & D. Inflamm Res 2005(Suppl 2):S92-3
   Google Scholar
• ICH. ICH M3(R2) - Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; 2009
   Google Scholar
• Chandran V, Cook RJ, Edwin J, Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010;49:1399-405
   PubMed Web of Science ®Google Scholar
• Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol 2011;20:81-7
   PubMed Web of Science ®Google Scholar
• Zaba LC, Cardinale I, Gilleaudeau P, Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94
   PubMed Web of Science ®Google Scholar
• Oestreicher JL, Walters IB, Kikuchi T, Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001;1:272-87
   PubMedGoogle Scholar
• Zhou X, Krueger JG, Kao MC, Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003;13:69-78
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Ding J, Li X, Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 2009;129:2795-804
   Google Scholar
• Guttman-Yassky E, Suarez-Farinas M, Chiricozzi A, Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 2009;124:1235-44
   PubMed Web of Science ®Google Scholar
• Racz E, Prens EP, Kurek D, Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol 2011;131:1547-58
   PubMed Web of Science ®Google Scholar
• Kim BE, Howell MD, Guttman E, TNF-alpha downregulates Filaggrin and Loricrin through c-Jun N-terminal Kinase: role for TNF-alpha antagonists to improve skin barrier. J Invest Dermatol 2011;131:1272-9
   PubMed Web of Science ®Google Scholar
• Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009;124:1022-10
   PubMed Web of Science ®Google Scholar
• Johansen C, Vinter H, Soegaard-Madsen L, Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFalpha therapy. Br J Dermatol 2010;163:1194-204
   PubMed Web of Science ®Google Scholar
• Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009;136:26-36
   PubMed Web of Science ®Google Scholar
• Suarez-Farinas M, Shah KR, Haider AS, Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept. BMC Dermatol 2010;10:1
   PubMedGoogle Scholar
• Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol 2011;131:391-400
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Boehncke S, Tobin AM, The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-7
   PubMed Web of Science ®Google Scholar
• Norsgaard H, Svensson L, Hagedorn PH, Translating clinical activity and gene expression signatures of etanercept and cyclosporine A to the psoriasis xenograft SCID mouse model. Br J Dermatol 2011; in press
   Web of Science ®Google Scholar